

## **Cancer Pain Market Report and Forecast 2024-2032**

Market Report (7 Days) | 2024-04-16 | 140 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$8999.00

### **Report description:**

Cancer Pain Market Report and Forecast 2024-2032

Cancer Pain Market Overview

The cancer pain market size was valued at USD 6.53 billion in 2023, driven by increasing cancer incidence and rising demand for effective therapeutics to manage cancer pain across the 8 major markets. The market is expected to grow at a CAGR of 5.60% during the forecast period of 2024-2032, with the values likely to rise from USD 6.9 billion in 2024 to USD 10.66 billion by 2032. Cancer pain is a complex and multidimensional symptom that affects the quality of life of cancer patients. Cancer pain can be caused by the tumor itself, the treatments, or the side effects of the treatments. Cancer pain can be acute or chronic, and can vary in intensity, frequency, and duration. The management of cancer pain involves a multidisciplinary approach that includes pharmacological and non-pharmacological interventions, such as opioids, non-opioids, adjuvants, nerve blocks, radiotherapy, surgery, psychological therapies, and complementary therapies.

Cancer Pain Market Drivers and Constraints

The key drivers of the global cancer pain market are:

- The increasing prevalence and incidence of cancer worldwide, especially in the aging population.
- The rising awareness and demand for effective pain management among cancer patients and caregivers.
- The development and launch of novel and innovative products, such as extended-release formulations, transdermal patches, and abuse-deterrent formulations, that offer better efficacy, safety, and convenience.
- The expansion of the indications and the patient population for existing products, such as opioids, adjuvants, and cannabinoids.
- The favorable reimbursement policies and government initiatives that support the access and affordability of cancer pain treatments.

The key constraints of the global cancer pain market are:

- The high cost and low availability of some of the cancer pain treatments, especially in the developing and underdeveloped regions.
- The stringent regulatory requirements and the long approval process for new products and indications.
- The lack of standardized guidelines and protocols for cancer pain assessment and management across different regions and settings.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- The low awareness and education among healthcare professionals and patients about the optimal use of cancer pain treatments.
- The social stigma and legal barriers associated with some of the cancer pain treatments, such as opioids and cannabinoids.

#### Cancer Pain Market Trends and Developments

- Increasing Incidence of Cancer: The rising global incidence of cancer is leading to a greater number of patients requiring pain management, thereby driving the demand for cancer pain treatments.
- Advancements in Pain Management Therapies: There is ongoing research and development of new analgesics, including non-opioid medications, targeted therapies, and combination treatments, to provide more effective and safer options for cancer pain management.
- Shift Towards Personalized Medicine: Personalized pain management approaches, based on the genetic makeup of patients and the specific characteristics of their cancer, are being explored to optimize treatment outcomes.
- Integration of Multimodal Approaches: The trend towards multimodal pain management, which combines pharmacological and non-pharmacological therapies (such as physical therapy, acupuncture, and psychological support), is gaining traction for a more holistic approach to cancer pain.
- Focus on Quality of Life: There is an increasing emphasis on assessing and improving the quality of life for cancer patients, with pain management being a crucial aspect of palliative care.
- Use of Advanced Drug Delivery Systems: Innovations in drug delivery systems, such as transdermal patches, implantable pumps, and extended-release formulations, are improving the efficacy and convenience of cancer pain treatments.
- Growing Awareness and Education: Efforts to raise awareness among healthcare professionals and patients about effective cancer pain management strategies are contributing to better pain control and treatment adherence.
- Regulatory Challenges and Opioid Concerns: The opioid crisis has led to stricter regulations and guidelines for prescribing opioid analgesics, impacting the cancer pain market and necessitating the development of alternative pain management options.

#### Cancer Pain Market Segmentation

##### Market Breakup by Drug Type?

- Opioids
  - o□Fentanyl
  - o□Morphine
  - o□Others
- Non-Opioids?
  - o□Acetaminophen
  - o□Non-Steroidal Anti-Inflammatory Drug
- Nerve Blockers

##### Market Breakup by Indication?Type

- Lung Cancer?
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Blood Cancer
- Others?

##### Market Breakup by Treatment Type

- Immunotherapy??
- Chemotherapy
- Targeted Therapy
- Hormonal Therapy

##### Market Breakup by Region

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- [ ] United States
- [ ] EU-4 and the United Kingdom
- o [ ] Germany
- o [ ] France
- o [ ] Italy
- o [ ] Spain
- o [ ] United Kingdom
- [ ] Japan
- [ ] India

#### Cancer Pain Market: Competitive Landscape

The market report encompasses comprehensive analyses, including patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, as well as partnerships and collaborations analysis conducted by the leading key players in the market. Among the major companies contributing to this market are Eli Lilly, HISAMITSU PHARMACEUTICAL CO., INC., Aoxing Pharmaceutical Company, Inc., GRUNENTHAL PHARMA GmbH & CO. KG, PFIZER INC., BIODELIVERY SCIENCES INTERNATIONAL, INC., OREXO AB, Johnson and Johnson, Medtronic plc, Novartis AG, and Glaxo SmithKline Plc. These analyses and the involvement of these prominent players highlight the dynamic and evolving nature of the market, underlining the significant investments and collaborations driving advancements and growth in the field.

#### Table of Contents:

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage - Key Segmentation and Scope
  - 1.4 Research Methodology
- 2 Executive Summary
- 3 Cancer Pain Overview
  - 3.1 Guidelines and Stages
  - 3.2 Pathophysiology
  - 3.3 Screening and Diagnosis
  - 3.4 Treatment Pathway
- 4 Patient Profile
  - 4.1 Patient Profile Overview
  - 4.2 Patient Psychology and Emotional Impact Factors
  - 4.3 Risk Assessment and Treatment Success Rate
- 5 Cancer Pain Epidemiology Analysis - 8MM
  - 5.1 8MM Epidemiology Scenario Overview (2017-2032)
  - 5.2 United States Cancer Pain Epidemiology Forecast (2017-2032)
  - 5.3 EU-4 and United Kingdom Cancer Pain Epidemiology Forecast (2017-2032)
    - 5.3.1 Germany Cancer Pain Epidemiology Forecast (2017-2032)
    - 5.3.2 France Cancer Pain Epidemiology Forecast (2017-2032)
    - 5.3.3 Italy Cancer Pain Epidemiology Forecast (2017-2032)
    - 5.3.4 Spain Cancer Pain Epidemiology Forecast (2017-2032)
    - 5.3.5 United Kingdom Cancer Pain Epidemiology Forecast (2017-2032)
  - 5.4 Japan Cancer Pain Epidemiology Forecast (2017-2032)
  - 5.5 India Cancer Pain Epidemiology Forecast (2017-2032)
- 6 Cancer Pain Market Overview - 8MM
  - 6.1 Cancer Pain Market Historical Value (2017-2023)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.2 Cancer Pain Market Forecast Value (2024-2032)
- 7 Cancer Pain Market Landscape - 8MM
  - 7.1 Amyotrophic Lateral Sclerosis: Developers Landscape
    - 7.1.1 Analysis by Year of Establishment
    - 7.1.2 Analysis by Company Size
    - 7.1.3 Analysis by Region
  - 7.2 Cancer Pain Product Landscape
    - 7.2.1 Analysis by Drug Type
    - 7.2.2 Analysis by Indication Type
    - 7.2.3 Analysis by Treatment Type
- 8 Cancer Pain Challenges and Unmet Needs
  - 8.1 Treatment Pathway Challenges
  - 8.2 Compliance and Drop-Out Analysis
  - 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Cancer Pain Market Dynamics
  - 10.1 Market Drivers and Constraints
  - 10.2 SWOT Analysis
  - 10.3 Porter's Five Forces Model
  - 10.4 Key Demand Indicators
  - 10.5 Key Price Indicators
  - 10.6 Industry Events, Initiatives, and Trends
  - 10.7 Value Chain Analysis
- 11 Cancer Pain Market Segmentation - 8MM
  - 11.1 Cancer Pain Market by Drug Type
    - 11.1.1 Market Overview
    - 11.1.2 Opioids
      - 11.1.2.1 Fentanyl
      - 11.1.2.2 Morphine
      - 11.1.2.3 Others
    - 11.1.3 Non-Opioids
      - 11.1.3.1 Acetaminophen
      - 11.1.3.2 Non-Steroidal Anti-Inflammatory Drugs
    - 11.1.4 Nerve Blockers
  - 11.2 Cancer Pain Market by Indication Type
    - 11.2.1 Market Overview
    - 11.2.2 Lung Cancer
    - 11.2.3 Colorectal Cancer
    - 11.2.4 Breast Cancer
    - 11.2.5 Prostate Cancer
    - 11.2.6 Blood Cancer
    - 11.2.7 Others
  - 11.3 Cancer Pain Market by Treatment Type
    - 11.3.1 Market Overview
    - 11.3.2 Immunotherapy
    - 11.3.3 Chemotherapy
    - 11.3.4 Targeted Therapy

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.3.5 Hormonal Therapy
- 11.4 Cancer Pain Market by Region
  - 11.4.1 Market Overview
  - 11.4.2 United States
  - 11.4.3 EU-4 and the United Kingdom
    - 11.4.3.1 Germany
    - 11.4.3.2 France
    - 11.4.3.3 Italy
    - 11.4.3.4 Spain
    - 11.4.3.5 United Kingdom
  - 11.4.4 Japan
  - 11.4.5 India
- 12 United States Cancer Pain Market
  - 12.1 Cancer Pain Market Historical Value (2017-2023)
  - 12.2 Cancer Pain Market Forecast Value (2024-2032)
  - 12.3 Cancer Pain Market by Drug Type
  - 12.4 Cancer Pain Market by Indication Type
- 13 EU-4 and United Kingdom Cancer Pain Market
  - 13.1 Cancer Pain Market Historical Value (2017-2023)
  - 13.2 Cancer Pain Market Forecast Value (2024-2032)
  - 13.3 Germany Cancer Pain Market Overview
    - 13.3.1 Cancer Pain Market by Drug Type
    - 13.3.2 Cancer Pain Market by Indication Type
  - 13.4 France Cancer Pain Market Overview
    - 13.4.1 Cancer Pain Market by Drug Type
    - 13.4.2 Cancer Pain Market by Indication Type
  - 13.5 Italy Cancer Pain Market Overview
    - 13.5.1 Cancer Pain Market by Drug Type
    - 13.5.2 Cancer Pain Market by Indication Type
  - 13.6 Spain Cancer Pain Market Overview
    - 13.6.1 Cancer Pain Market by Drug Type
    - 13.6.2 Cancer Pain Market by Indication Type
  - 13.7 United Kingdom Cancer Pain Market Overview
    - 13.7.1 Cancer Pain Market by Drug Type
    - 13.7.2 Cancer Pain Market by Indication Type
- 14 Japan Cancer Pain Market
  - 14.1 Cancer Pain Market Historical Value (2017-2023)
  - 14.2 Cancer Pain Market Forecast Value (2024-2032)
  - 14.3 Cancer Pain Market by Drug Type
  - 14.4 Cancer Pain Market by Indication Type
- 15 India Cancer Pain Market
  - 15.1 Cancer Pain Market Historical Value (2017-2023)
  - 15.2 Cancer Pain Market Forecast Value (2024-2032)
  - 15.3 Cancer Pain Market by Drug Type
  - 15.4 Cancer Pain Market by Indication Type
- 16 Regulatory Framework
  - 16.1 Regulatory Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 16.1.1 US FDA
- 16.1.2 EU EMA
- 16.1.3 India CDSCO
- 16.1.4 JAPAN PMDA
- 17 Patent Analysis
  - 17.1 Analysis by Type of Patent
  - 17.2 Analysis by Publication year
  - 17.3 Analysis by Issuing Authority
  - 17.4 Analysis by Patent Age
  - 17.5 Analysis by CPC Analysis
  - 17.6 Analysis by Patent Valuation
  - 17.7 Analysis by Key Players
- 18 Grants Analysis
  - 18.1 Analysis by year
  - 18.2 Analysis by Amount Awarded
  - 18.3 Analysis by Issuing Authority
  - 18.4 Analysis by Grant Application
  - 18.5 Analysis by Funding Institute
  - 18.6 Analysis by NIH Departments
  - 18.7 Analysis by Recipient Organization
- 19 Clinical Trials Analysis
  - 19.1 Analysis by Trial Registration Year
  - 19.2 Analysis by Trial Status
  - 19.3 Analysis by Trial Phase
  - 19.4 Analysis by Therapeutic Area
  - 19.5 Analysis by Geography
- 20 Funding and Investment Analysis
  - 20.1 Analysis by Funding Instances
  - 20.2 Analysis by Type of Funding
  - 20.3 Analysis by Funding Amount
  - 20.4 Analysis by Leading Players
  - 20.5 Analysis by Leading Investors
  - 20.6 Analysis by Geography
- 21 Partnerships and Collaborations Analysis
  - 21.1 Analysis by Partnership Instances
  - 21.2 Analysis by Type of Partnership
  - 21.3 Analysis by Leading Players
  - 21.4 Analysis by Geography
- 22 Supplier Landscape
  - 22.1 Eli Lilly
    - 22.1.1 Financial Analysis
    - 22.1.2 Product Portfolio
    - 22.1.3 Demographic Reach and Achievements
    - 22.1.4 Mergers and Acquisitions
    - 22.1.5 Certifications
  - 22.2 HISAMITSU PHARMACEUTICAL CO., INC.,
    - 22.2.1 Financial Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 22.2.2 Product Portfolio
- 22.2.3 Demographic Reach and Achievements
- 22.2.4 Mergers and Acquisitions
- 22.2.5 Certifications
- 22.3 Aoxing pharmaceutical company, inc.,
  - 22.3.1 Financial Analysis
  - 22.3.2 Product Portfolio
  - 22.3.3 Demographic Reach and Achievements
  - 22.3.4 Mergers and Acquisitions
  - 22.3.5 Certifications
- 22.4 GRUNENTHAL PHARMA GmbH & CO. KG
  - 22.4.1 Financial Analysis
  - 22.4.2 Product Portfolio
  - 22.4.3 Demographic Reach and Achievements
  - 22.4.4 Mergers and Acquisitions
  - 22.4.5 Certifications
- 22.5 PFIZER INC.,
  - 22.5.1 Financial Analysis
  - 22.5.2 Product Portfolio
  - 22.5.3 Demographic Reach and Achievements
  - 22.5.4 Mergers and Acquisitions
  - 22.5.5 Certifications
- 22.6 BIODELIVERY SCIENCES INTERNATIONAL, INC.,
  - 22.6.1 Financial Analysis
  - 22.6.2 Product Portfolio
  - 22.6.3 Demographic Reach and Achievements
  - 22.6.4 Mergers and Acquisitions
  - 22.6.5 Certifications
- 22.7 OREXO AB
  - 22.7.1 Financial Analysis
  - 22.7.2 Product Portfolio
  - 22.7.3 Demographic Reach and Achievements
  - 22.7.4 Mergers and Acquisitions
  - 22.7.5 Certifications
- 22.8 Johnson and Johnson
  - 22.8.1 Financial Analysis
  - 22.8.2 Product Portfolio
  - 22.8.3 Demographic Reach and Achievements
  - 22.8.4 Mergers and Acquisitions
  - 22.8.5 Certifications
- 22.9 Medtronic plc
  - 22.9.1 Financial Analysis
  - 22.9.2 Product Portfolio
  - 22.9.3 Demographic Reach and Achievements
  - 22.9.4 Mergers and Acquisitions
  - 22.9.5 Certifications
- 22.10 Novartis AG

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 22.10.1 Financial Analysis
- 22.10.2 Product Portfolio
- 22.10.3 Demographic Reach and Achievements
- 22.10.4 Mergers and Acquisitions
- 22.10.5 Certifications
- 22.11 Glaxo SmithKline Plc
  - 22.11.1 Financial Analysis
  - 22.11.2 Product Portfolio
  - 22.11.3 Demographic Reach and Achievements
  - 22.11.4 Mergers and Acquisitions
  - 22.11.5 Certifications
- 23 Cancer Pain Market- Distribution Model (Additional Insight)
  - 23.1 Overview
  - 23.2 Potential Distributors
  - 23.3 Key Parameters for Distribution Partner Assessment
- 24 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 25 Company Competitiveness Analysis (Additional Insight)
  - 25.1 Very Small Companies
  - 25.2 Small Companies
  - 25.3 Mid-Sized Companies
  - 25.4 Large Companies
  - 25.5 Very Large Companies
- 26 Payment Methods (Additional Insight)
  - 26.1 Government Funded
  - 26.2 Private Insurance
  - 26.3 Out-of-Pocket

\*Additional insights provided are customisable as per client requirements.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



**Cancer Pain Market Report and Forecast 2024-2032**

Market Report (7 Days) | 2024-04-16 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$8999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-10"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com